Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022008597 - METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INFECTIOUS DISEASES

Publication Number WO/2022/008597
Publication Date 13.01.2022
International Application No. PCT/EP2021/068845
International Filing Date 07.07.2021
IPC
A61K 31/167 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
165having aromatic rings, e.g. colchicine, atenolol, progabide
167having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 38/05 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
05Dipeptides
A61P 11/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
A61P 31/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P 31/04 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
04Antibacterial agents
A61P 31/12 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
Applicants
  • INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) [FR]/[FR]
  • CENTRE HOSPITALIER UNIVERSITAIRE DE NICE [FR]/[FR]
  • UNIVERSITE COTE D'AZUR [FR]/[FR]
Inventors
  • AUBERGER, Patrick
  • CHAINTREUIL, Paul
  • DUFIES, Océane
  • COURJON, Johan
  • BOYER, Laurent
  • JACQUEL, Arnaud
Agents
  • INSERM TRANSFERT
Priority Data
20305782.308.07.2020EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INFECTIOUS DISEASES
(FR) MÉTHODES ET COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT DE MALADIES INFECTIEUSES
Abstract
(EN) The invention relates to a pan caspase inhibitor for use in the treatment of lung infection (such as Syndrome-Corona Virus (SARS-CoV) infection and SARS-COV related disorders) in a subject in need thereof. The current COVID-19 pandemic is predicted to last several additional months, further increasing mortality rates, especially in the more fragile populations. Inventors have surprisingly found that Emricasan is able to efficiently inhibit caspase-8 which is involved in the inflammation process. More particularly, inventors have shown that Emricasan blocks caspase-1 activation in monocytes from healthy donor or COVID19 patient. This new finding with either Emricasan alone or in combination with other therapeutics seem to be very promising in patients suffering from an infectious disease, more particularly an infection caused by Syndrome-Corona Virus.
(FR) L'invention concerne un inhibiteur pan-caspase destiné à être utilisé dans le traitement d'une infection pulmonaire (telle qu'une infection par un coronavirus à l'origine d'un syndrome (SARS-CoV-2) et des troubles liés au SARS-CoV) chez un sujet qui en a besoin. On prédit que la pandémie de COVID-19 actuelle devrait durer plusieurs mois supplémentaires, augmentant encore les taux de mortalité, en particulier chez les populations les plus fragiles. Les inventeurs ont découvert de manière surprenante que l'Emricasan peut inhiber efficacement la caspase-8 qui est impliquée dans le processus d'inflammation. Plus particulièrement, les inventeurs ont démontré que l'Emricasan bloque l'activation de la caspase-1 dans des monocytes en provenance d'un donneur sain ou d'un patient atteint de COVID-19. Cette nouvelle découverte avec de l'Emricasan seul ou en association avec d'autres agents thérapeutiques semble être très prometteuse chez des patients souffrant d'une maladie infectieuse, plus particulièrement d'une infection provoquée par le coronavirus à l'origine d'un syndrome.
Latest bibliographic data on file with the International Bureau